Revenue and Top-Line Growth
Reported revenue of greater than $2.7 billion in Q1 2026, representing consolidated sales growth of 3% year-over-year on a currency-neutral basis driven by volume improvements across all businesses.
Adjusted Operating EBITDA and Margin Expansion
Adjusted operating EBITDA totaled $568 million, up 8% year-over-year. Adjusted EBITDA margin expanded by 110 basis points to 20.7%, the highest EBITDA margin since 2022.
Segment Profitability Improvements — Taste
Taste sales rose 2% to $656 million. Adjusted operating EBITDA for Taste increased 18% year-over-year to $153 million, driven by volume growth, favorable net pricing, and productivity gains.
Strong Performance — Food Ingredients
Food Ingredients sales increased 3% to $839 million with volume growth of approximately 5% (the highest in several years). Adjusted operating EBITDA grew 12% year-over-year to $114 million.
Health & Biosciences Growth
Health & Biosciences delivered sales of $595 million, up 5% year-over-year (all volume-driven) with adjusted operating EBITDA up 7% to $153 million, led by Animal Nutrition and Food Biosciences.
Cash Flow and Balance Sheet Progress
Cash flow from operations was $257 million (+$130 million YoY). Free cash flow was $92 million, up $144 million YoY. Gross debt declined to $5.85 billion, more than $3 billion lower than prior-year. Net debt to credit-adjusted EBITDA was ~2.5x.
Capital Returns and Financial Discipline
Returned $102 million to shareholders via dividends and $35 million through the dilution-cost share repurchase program in Q1, while maintaining disciplined capital allocation and a stated leverage target around 2.5x net debt/EBITDA.
Strategic Portfolio Actions and Investments
Completed divestiture of commodity soy crush, concentrates, and lecithin business for $110 million (closed March 2). Sale process for Food Ingredients progressing with positive buyer interest; new production and innovation capacity added in Latin America (Areito fermentation site in Argentina and household care lab in Brazil).
Full-Year 2026 Guidance Reaffirmed
Reaffirmed FY26 guidance: sales $10.5B–$10.8B (1%–4% growth) and adjusted operating EBITDA $2.05B–$2.15B (3%–8% growth). Foreign exchange expected to add roughly +1 percentage point to full-year sales growth.